Advertisement
Original article| Volume 14, ISSUE 10, P1521-1529, October 2018

Download started.

Ok

Effect of laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy on fasting gastrointestinal and pancreatic peptide hormones: A prospective nonrandomized trial

      Abstract

      Background

      Changes in gastrointestinal and pancreatic hormones may play a role in promoting long-term weight reduction and improved glucose metabolism after sleeve gastrectomy and Roux-en-Y gastric bypass. However, few studies have examined the metabolic and endocrine effects of these procedures in Mainland China.

      Objectives

      To compare the effects of laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB) on gastrointestinal and pancreatic peptide hormones.

      Setting

      University hospital, China.

      Methods

      A nonrandomized prospective study was conducted in Chinese obese patients undergoing LSG or LRYGB. Of 20 patients in this study, 10 underwent LSG, and 10 underwent LRYGB. Fasting plasma levels of insulin, glucagon, ghrelin, gastric inhibitory peptide, peptide YY, glucagon-like peptide (GLP)-1, and GLP-2 were measured preoperatively and at 1, 3, 6, and 12 months after surgery. This trial was registered at www.clinicaltrials.gov (NCT02963662).

      Results

      During the first year after both operations, mean body mass index and fasting insulin levels steadily decreased at all intervals. Fasting plasma glucose levels significantly decreased at 1 month after surgery, then remained stable in both groups. Glucagon levels significantly decreased at 1, 3, and 6 months after surgery in both groups, but returned to baseline at 12 months. Fasting GLP-1 and peptide YY significantly increased in both groups, but more so after LRYGB. However, GLP-2 did not change in either group. Ghrelin levels significantly decreased after LSG, but not after LRYGB. Gastric inhibitory peptide levels decreased after LRYGB but not after LSG.

      Conclusions

      LSG and LRYGB resulted in significant and distinct changes in multiple gastrointestinal and pancreatic peptide hormones that are important regulators of obesity and metabolic health.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery for Obesity and Related Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cesare MD
        • Bentham J
        • Stevens GA
        • et al.
        Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants.
        Lancet. 2016; 387: 1377-1396
        • Sala PC
        • Torrinhas RS
        • Giannellaneto D
        • et al.
        Relationship between gut hormones and glucose homeostasis after bariatric surgery.
        Diabetol Metabol Syndr. 2014; 6: 1-12
        • Dicker D
        • Yahalom R
        • Comaneshter DS
        • et al.
        Long-term outcomes of three types of bariatric surgery on obesity and type 2 diabetes control and remission.
        Obes Surg. 2016; 26: 1814-1820
        • Santry HP
        • Gillen DL
        • Lauderdale DS
        Trends in bariatric surgical procedures.
        JAMA. 2005; 294: 1909-1917
        • Smith BR
        • Schauer P
        • Nguyen NT
        Surgical approaches to the treatment of obesity: bariatric surgery.
        Endocrinol Metab Clin North Am. 2008; 37: 943-964
        • Juodeikis Ž
        • Brimas G
        Long-term results after sleeve gastrectomy: a systematic review.
        Surg Obes Relat Dis. 2017; 13: 693-699
        • Ramón JM
        • Salvans S
        • Crous X
        • et al.
        Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial.
        J Gastrointest Surg. 2012; 16: 1116-1122
        • Peterli R
        • Wölnerhanssen B
        • Peters T
        • et al.
        Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial.
        Ann Surg. 2009; 250: 234-241
        • Nosso G
        • Griffo E
        • Cotugno M
        • et al.
        Comparative effects of Roux-en-Y gastric bypass and sleeve gastrectomy on glucose homeostasis and incretin hormones in obese type 2 diabetic patients: a one-year prospective study.
        Horm Metab Res. 2016; 48: 312-317
        • Jacobsen SH
        • Dirksen C
        • Jørgensen NB
        • et al.
        Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects.
        Obes Surg. 2012; 22: 1084-1096
        • Romero F
        • Nicolau J
        • Flores L
        • et al.
        Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects.
        Surg Endosc. 2012; 26: 2231-2239
        • Umeda LM
        • Silva EA
        • Carneiro G
        • et al.
        Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients.
        Obes Surg. 2011; 21: 896-901
        • Malin SK
        • Kashyap SR
        Differences in weight loss and gut hormones: Rou-en-Y gastric bypass and sleeve gastrectomy surgery.
        Curr Obes Rep. 2015; 4: 279-286
        • Meek CL
        • Lewis HB
        • Reimann F
        • et al.
        The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones.
        Peptides. 2015; 77: 28-37
        • Beckman LM
        • Beckman TR
        • Sibley SD
        • et al.
        Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery.
        JPEN J Parenter Enternal Nutr. 2011; 35: 169-180
        • Farey JE
        • Preda TC
        • Fisher OM
        • et al.
        Effect of laparoscopic sleeve gastrectomy on fasting gastrointestinal, pancreatic, and adipose-derived hormones and on non-esterified fatty acids.
        Obes Surg. 2017; 27: 399-407
        • Batterham RL
        • Heffron H
        • Kapoor S
        • et al.
        Critical role for peptide YY in protein-mediated satiation and body-weight regulation.
        Cell Metabol. 2006; 4: 223-233
        • Karamanakos SN
        • Vagenas K
        • Kalfarentzos F
        • et al.
        Weight loss, appetite suppression, and changes in fasting and postprandial Ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study.
        Ann Surg. 2008; 247: 401-407
        • Alamuddin N
        • Vetter ML
        • Ahima RS
        • et al.
        Changes in fasting and prandial gut and adiposity hormones following vertical sleeve gastrectomy or Roux-en-Y-gastric bypass: an 18-month prospective study.
        Obes Surg. 2017; 27: 1563-1572
        • Chandarana K
        • Gelegen C
        • Karra E
        • et al.
        Diet and gastrointestinal bypass-induced weight loss: the roles of Ghrelin and peptide YY.
        Diabetes. 2011; 60: 810-818
        • Date Y
        • Kojima M
        • Hosoda H
        • et al.
        Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans.
        Endocrinology. 2000; 141: 4255-4261
        • Tong J
        • Prigeon RL
        • Davis HW
        • et al.
        Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans.
        Diabetes. 2010; 59: 2145-2151
        • Malin S K
        • Samat A
        • Wolski K
        • et al.
        Improved acylated Ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs standard medical therapy.
        Int J Obes. 2013; 38: 364-370
        • Martins C
        • Kjelstrup L
        • Mostad IL
        • et al.
        Impact of sustained weight loss achieved through Roux-en-Y gastric bypass or a lifestyle intervention on Ghrelin, obestatin, and Ghrelin/obestatin ratio in morbidly obese patients.
        Obesity Surgery. 2011; 21: 751-758
        • Chambers AP
        • Kirchner H
        • Wilson-Perez HE
        • et al.
        The effects of vertical sleeve gastrectomy in rodents are Ghrelin independent.
        Gastroenterology. 2013; 144 (e55): 50-52
        • Meier JJ
        • Gallwitz B
        • Salmen S
        • et al.
        Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
        J Clin Endocrinol Metab. 2003; 88: 2719-2725
        • Gallwitz B.
        Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advances.
        Curr Opin Endocrinol Diabetes Obes. 2016; 23: 23-27
        • Le RC
        • Borg CK
        • Vincent RP
        • et al.
        Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation.
        Ann Surg. 2010; 252: 50-56
        • Ionut V
        • Burch M
        • Youdim A
        • et al.
        Gastrointestinal hormones and bariatric surgery-induced weight loss.
        Obesity. 2013; 21: 1093-1103
        • Ye J
        • Hao Z
        • Mumphrey MB
        • et al.
        GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.
        Am J Physiol Regul Comp Physiol. 2014; 306: R352-R362
        • Wilsonpérez HE
        • Chambers AP
        • Ryan KK
        • et al.
        Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency.
        Diabetes. 2013; 62: 2380-2385
        • Rao RS
        • Kini S
        GIP and bariatric surgery.
        Obes Surg. 2011; 21: 244-252
        • Miyawaki K
        • Yamada Y
        • Ban N
        • et al.
        Inhibition of gastric inhibitory polypeptide signaling prevents obesity.
        Nat Med. 2002; 8: 738-742
        • Falkén Y
        • Hellström PM
        • Holst JJ
        • et al.
        Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides.
        J Clin Endocrinol Metabol. 2011; 96: 2227-2235
        • Korner J
        • Bessler M
        • Inabnet W
        • et al.
        Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding.
        Surg Obes Relat Dis. 2007; 3: 597-601
        • Batterham RL
        • Cummings DE
        Mechanisms of diabetes improvement following bariatric/metabolic surgery.
        Diabetes Care. 2016; 39: 893-901
        • Shukla A
        • Rubino F
        Secretion and function of gastrointestinal hormones after bariatric surgery: their role in type 2 diabetes.
        Can J Diabetes. 2011; 35: 115-122
        • Thomas F
        • Smith GC
        • Lu J
        • et al.
        Differential acute impacts of sleeve gastrectomy, Roux-en-Y gastric bypass surgery and matched caloric restriction diet on insulin secretion, insulin effectiveness and non-esterified fatty acid levels among patients with type 2 diabetes.
        Obes Surg. 2016; 26: 1924-1931
        • Shoar S
        • Saber AA
        Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies.
        Surg Obes Relat Dis. 2016; 13: 170-180
        • Swarbrick MM
        • Stanhope KL
        • Austrheim-Smith IT
        • et al.
        Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery.
        Diabetologia. 2008; 51: 1901-1911
        • Nannipieri M
        • Baldi S
        • Mari A
        • et al.
        Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones.
        J Clin Endocrinol Metabol. 2013; 98: 4391-4399